

April 28, 2020

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Launched new product with the name “COROVYL” for Viral Infection

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject we, Zota Health Care Limited (the “Company”) are delighted to inform you that we have launched new product with the name “COROVYL” (the “Product”). This product shall be useful in treatment of Viral Infection and Viral Fever.

COROVYL is Ayurvedic Proprietary Medicine and is being made after carrying out necessary research by experts. The product will enhance the immunity power of the patient and shall also help patient to recover from Viral Infection and Viral Fever. In current pandemic, this product shall turn to be as elixir. This product has been approved by Food and Drug Control Administration of Gujarat State.


The product has been developed in technical collaboration with Ayursun Pharma, which is leading ayurvedic medicine manufacturer.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited



Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat



Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122